Advaxis Inc. (ADXS) Shares Up 3.7%
Advaxis Inc. (NASDAQ:ADXS) shot up 3.7% during trading on Wednesday . The company traded as high as $8.41 and last traded at $8.33, with a volume of 221,906 shares changing hands. The stock had previously closed at $8.03.
A number of brokerages have recently commented on ADXS. FBR & Co reiterated an “outperform” rating and set a $34.00 price objective on shares of Advaxis in a research report on Tuesday, May 17th. HC Wainwright reiterated a “buy” rating on shares of Advaxis in a research report on Wednesday, June 29th. Finally, Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research report on Friday, June 10th. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $24.80.
The firm’s market capitalization is $283.70 million. The stock’s 50 day moving average price is $8.18 and its 200-day moving average price is $7.97.
In related news, Director Thomas J. Mckearn sold 4,100 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the sale, the director now owns 82,120 shares of the company’s stock, valued at $611,794. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel O’connor sold 8,237 shares of the firm’s stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $7.51, for a total transaction of $61,859.87. Following the completion of the sale, the chief executive officer now directly owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The disclosure for this sale can be found here.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.